REG - Haleon PLC - Total Voting Rights and Capital

HALEONAnnouncement

21/03/2024 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU8540Ha&default-theme=true

RNS Number : 8540H  Haleon PLC  21 March 2024

 

 

Haleon plc: Total Voting Rights and Capital

 

21 March 2024: Haleon plc ("Haleon" or the "Company) announces that the
Company has today cancelled 102,272,727 ordinary shares of £0.01 each,
repurchased from Pfizer Inc.

 

As at 21 March 2024 the total number of shares issued by Haleon plc with
rights to vote is 9,132,301,104 ordinary shares of £0.01 each. There are no
ordinary shares held in Treasury.

 

The figure of 9,132,301,104 may be used by shareholders (and others with
notification obligations) as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

The person responsible for arranging the release of this announcement on
behalf of Haleon is Amanda Mellor, Company Secretary.

 

 

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRUAONRSVUOUAR